The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 18, 2018
Filed:
Sep. 11, 2017
Applicant:
Allgenesis Biotherapeutics Inc., Taipei, TW;
Inventors:
Tan Nguyen, Fullerton, CA (US);
Chin-yu Lai, Taipei, TW;
Assignee:
Allgenesis Biotherapeutics, Inc., Taipei, TW;
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 9/00 (2006.01); A61K 9/14 (2006.01); A61K 31/44 (2006.01); A61K 31/496 (2006.01); A61K 31/506 (2006.01); A61K 31/4439 (2006.01);
U.S. Cl.
CPC ...
A61K 31/496 (2013.01); A61K 9/0048 (2013.01); A61K 9/146 (2013.01); A61K 31/44 (2013.01); A61K 31/4439 (2013.01); A61K 31/506 (2013.01);
Abstract
Ophthalmic formulations containing tyrosine kinase inhibitors, such as Nintedanib, Axitinib, Sorafenib, and Pazopanib are described. The ophthalmic formulations can contain microparticles or nanoparticles of the tyrosine kinase inhibitor. Also described are methods of using the ophthalmic formulations for treating ocular surface diseases, such pterygium, including recurrent pterygium, and hyperemia associated with pterygium.
Nguyen, Tan. (2018). Ophthalmic formulations of tyrosine kinase inhibitors, methods of use thereof, and preparation methods thereof (U.S. Patent No. 10154994). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/10154994
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile